Modality
mRNA
MOA
BiTE
Target
VEGF
Pathway
STING
SCLC
Development Pipeline
Preclinical
~Oct 2012
→ ~Jan 2014
Phase 1
~Apr 2014
→ ~Jul 2015
Phase 2
~Oct 2015
→ ~Jan 2017
Phase 3
~Apr 2017
→ ~Jul 2018
NDA/BLA
Oct 2018
→ Feb 2026
NDA/BLACurrent
NCT08605774
1,418 pts·SCLC
2018-10→2026-02·Recruiting
1,418 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-02-201mo agoPh3 Readout· SCLC
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2026-02-20 · 1mo ago
SCLC
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08605774 | NDA/BLA | SCLC | Recruiting | 1418 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF |